Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Licenses Hypotension Drug To Local Startup

This article was originally published in PharmAsia News

Executive Summary

Astellas Pharma of Japan licensed to a Keio University startup, Signal Creation, a drug it had abandoned earlier during development. Astellas inherited FK352, a drug to treat dialysis-related hypotension, when Fujisawa Pharmaceutical and Yamanouchi Pharmaceutical merged to form Astellas in 2005. The drug got through Phase II trials before it was pulled back on concerns it would not be profitable. Astellas has several other compounds it has shelved in the past that also could be licensed. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068914

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel